跳至主要内容
临床试验/NCT06592547
NCT06592547已完成2 期

EFFECT of INTRAVENOUS METOPROLOL TARTRATE on MORTALITY in PATIENTS with SEPTIC SHOCK DUE to VENTILATOR-ASSOCIATED PNEUMONIA Thesis

Alexandria University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
试验地点
1
主要终点
28-day Mortality

研究概览

简要总结

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

详细描述

A RCT, conducted at alexandria main university hospital, patients were divided into 2 groups, Control group which received the standard care for septic shock and metoprolol group which recieved intravenous metoprolol then patients were assessed for Blood pressure, heart rate, iv fluids needed, vasopressor doses and 28 days mortality

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The study population included adult patients (≥ 18 years) diagnosed with septic shock secondary to VAP with sinus tachycardia, from April 1, 2022, to April 31,
  • Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). VAP was identified as per the guidelines provided by the American Thoracic Society and Infectious Diseases Society of America.

排除标准

  • Patients were excluded if they had contraindications to beta-blockers, had a history of heart failure, or had been receiving beta-blockers prior to the septic shock. Patients were also excluded if they developed complications from beta- blockers administration.

研究组 & 干预措施

Metoprolol group

Active Comparator

The group that received intravenous metoprolol

干预措施: Intravenous metoprolol tartrate (Drug)

Control group

Placebo Comparator

The group that received standard care

干预措施: Standard Care (in control arm) (Other)

结局指标

主要结局

28-day Mortality

时间窗: 28 days

次要结局

  • ICU stay(28 days)
  • ventilator days(28 days)
  • iv fluids(28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sherouk Rafik

Resident

Alexandria University

研究点 (1)

Loading locations...

相似试验